Suzhou Alphamab Co., Ltd.
10
4
7
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
30%
3 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
Role: lead
To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients
Role: lead
To Evaluate the Efficacy and Safety of KN060 in Essential Hypertension
Role: lead
A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight
Role: lead
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors
Role: lead
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors
Role: lead
Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
Role: lead
KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia
Role: lead
A Study to Evaluate Effects of KN056 in Healthy Participants
Role: lead
KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors
Role: lead
All 10 trials loaded